Pharmacoeconomics: What is it and where is it going?

American Journal of Hypertension

Volumn 11, Issue 8 II SUPPL., 1998, Pages

  McCombs, Jeffrey S ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Clinical economics; Cost per quality adjusted life year; Cost effectiveness analysis; Pharmacoeconomics; Quality of life

Indexed keywords

HYDROCHLOROTHIAZIDE; NIFEDIPINE; PRAVASTATIN; PRAZOSIN; PROPRANOLOL; SIMVASTATIN;

ALGORITHM; BREAST CANCER; CANCER SCREENING; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; COST EFFECTIVENESS ANALYSIS; ENVIRONMENTAL MONITORING; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MEDICAL DECISION MAKING; NOTE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RADIATION MONITORING; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0031818335     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(98)00108-3     Document Type: Note

References (19)

1. Sloan FA: Introduction, in Sloan FA (ed): Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, Cambridge, England, 1995.
2. McKinlay JB: From "promising report" to "standard procedure": seven stages in the career of a medical innovation. Milibank Memorial Fund Quarterly/ Health and Society 1981;59:374-411.
3. Eddy DM, Billings J: The quality of medical evidence: implications for quality of care. Health Affairs 1988;7: 19-32.
4. Burner ST, Waldo DR, McKusick DR: National health expenditures projections through 2030. Health Care Financing Review 1992;14:1-30.
5. 1988 Joint National Committee: The 1988 report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med 1988;148:1023-1038.
6. Clark LT: Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J 1991;121:664-669.
7. U.S. Department of Health and Human Services: Inspector General, DHHS. Medication regimens: Causes of non-compliance. Washington, D.C., 1990.
8. Vital and Health Statistics: Current estimates for the National Health Interview Survey, 1993. U.S. Department of Health and Human Services, Center for National Health Statistics, Series 10, No. 190, Tables 58 and 59, December 1994.
9. Patrick DL, Erickson P: Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. Oxford University Press, New York, 1993.
10. Keeler E: Decision trees and Markov models in cost-effectiveness research, in Sloan FA (ed): Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, Cambridge, England, 1995.
11. Simon GE, VonKorff M, Heiligenstein JH, et al: Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-1902.
12. McCombs JS, Nichol MB, Newman CM, Sclar DA: The costs of interrupting antihypertensive drug therapy in a Medicaid population. Medical Care 1994;32:214-226.
13. Ashraf TA, Hay JW, Pitt B, et al: Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78:409-414.
14. Dranove D: Measuring cost, in Sloan FA (ed): Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, Cambridge, England, 1995.
15. Viscusi WK: Discounting health effects for medical decisions, in Sloan FA (ed): Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, Cambridge, England, 1995.
16. Hays RD, Sherbourne CD, Mazel RM: The RAND 36-item health survey 1.0. Economics 1993;2:217-227.
17. Kaplan RM: Utility assessment for estimating quality-adjusted life years, in Sloan FA (ed): Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, Cambridge, England, 1995.
18. Mullahy J, Manning W: Statistical issues in cost-effectiveness analyses, in Sloan FA (ed): Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, Cambridge, England, 1995.
19. Tengs TO, Adams ME, Pliskin JS, et al: Five-hundred live-saving interventions and their cost-effectiveness. Risk Analysis 1995;15:369-390.